49 studies found for:    "Alpha 1-antitrypsin deficiency"
Show Display Options
Rank Status Study
21 Active, not recruiting Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Genetic: rAAV2-CB-hAAT Gene Vector
22 Active, not recruiting Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Biological: rAAV1-CB-hAAT
23 Active, not recruiting Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Conditions: Emphysema;   Alpha 1-proteinase Inhibitor Deficiency
Intervention: Biological: Alpha1- proteinase inhibitor [human]
24 Completed
Has Results
Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
Condition: Alpha 1-Antitrypsin Deficiency
Interventions: Biological: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor;   Biological: Dose of 60 mg/kg alpha1-proteinase inhibitor
25 Completed Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor (API) Deficiency
Conditions: Alpha1-proteinase Inhibitor Deficiency;   Emphysema
Interventions: Biological: Alpha1-proteinase inhibitor;   Other: Placebo
26 Completed 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: 4-PBA
27 Recruiting Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
Condition: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Biological: Alpha1-proteinase inhibitor (human), modified process (Alpha-1 MP);   Other: 0.9% Sodium Chloride for Injection, USP
28 Completed Alpha1-antitrypsin Deficiency Registry
Conditions: Lung Diseases;   Emphysema;   Alpha-1 Antitrypsin Deficiency;   Chronic Obstructive Pulmonary Disease
Intervention:
29 Recruiting Alpha-1 Foundation Research Registry
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
30 Completed Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
Conditions: Emphysema;   Lung Diseases, Obstructive;   Alpha 1-Antitrypsin Deficiency
Intervention:
31 Completed
Has Results
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: alpha-1 proteinase inhibitor (human)
32 Recruiting Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Condition: Alpha 1 Antitrypsin Deficiency
Intervention: Drug: Alpha-1 Antitrypsin (human)
33 Recruiting Phase II, Safety and ELF Study of "Kamada-API for Inhalation"
Condition: Alpha-1 Antitrypsin Deficiency
Interventions: Biological: Kamada-API for Inhalation, 80mg;   Drug: Placebo;   Biological: Kamada-API for Inhalation, 160mg
34 Recruiting Alpha-1 Coded Testing(ACT) Study
Condition: Alpha-1 Antitrypsin Deficiency
Intervention: Procedure: Alpha-1 Antitrypsin Genotype
35 Completed
Has Results
GLASSIA Infusion Rate Study
Conditions: Alpha1-antitrypsin Deficiency;   Healthy
Interventions: Biological: Alpha1-proteinase inhibitor;   Biological: Placebo: Human albumin 2.5%
36 Recruiting Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)
Conditions: Liver Diseases;   Alagille Syndrome;   Alpha 1-Antitrypsin Deficiency
Intervention:
37 Completed Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
38 Active, not recruiting Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of Lungs After Ex-vivo Perfusion w/ STEEN Solution™;   Device: Steen Solution™
39 Recruiting Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™;   Device: STEEN Solution™
40 Enrolling by invitation Alpha-1 Foundation DNA and Tissue Bank
Condition: Alpha 1 Antitrypsin Deficiency
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-49) Show next page of results
Indicates status has not been verified in more than two years